ArticleEcancermedicalscience2018
Palliative chemotherapy outcomes in patients with ECOG-PS higher than 1.
Article in Ecancermedicalscience, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 2 syntheses or guidelines pooled it, 49 citations in OpenAlex.
- Pooled it
- Patient performance status and cancer immunotherapy efficacy: a meta-analysis.Medical oncology (Northwood, London, England) · 2018Pooled it
- Overall survival following palliative immune checkpoint inhibitor treatment according to ECOG performance status: a large registry-based study.Acta oncologica (Stockholm, Sweden) · 2026Article
- Gemcitabine-Based versus Fluoropyrimidine-Based Chemotherapy and Role of Platinum Combination for First-Line Palliative Systemic Treatment in Advanced Ampullary Adenocarcinoma.Cancer management and research · 2026Article
- Examining inpatient chemotherapy utilization among patients with cancer and impact on outcomes.The oncologist · 2025Article
- Differences in immune-related toxicity between PD-1 and PD-L1 inhibitors: a retrospective cohort study in patients with advanced cancer.Cancer immunology, immunotherapy : CII · 2024Article
- Factors Associated With Long Survival in Patients With Cancer Admitted to Palliative Care: An Exploratory Study.Journal of palliative care · 2024Article
- Predicting immune-related adverse events using a simplified frailty score in cancer patients treated with checkpoint inhibitors: A retrospective cohort study.Cancer medicine · 2023Article
- Clinical factors associated with outcome in solid tumor patients treated with immune-checkpoint inhibitors: a single institution retrospective analysis.Discover oncology · 2022Article
- An Analysis of Tolerance and Early Survival Outcomes with Perioperative Modified FLOT in Gastric Cancers.South Asian journal of cancer · 2022Article
- Article
- Pembrolizumab for treating advanced urothelial carcinoma in patients with impaired performance status: Analysis of a Japanese nationwide cohort.Cancer medicine · 2021Article
- Article
- Factors associated with the initiation of chemotherapy within 90 days of death in metastatic colorectal cancer patients: a population-based study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2021Article
- A Nomogram for Predicting Risk of Thromboembolism in Gastric Cancer Patients Receiving Chemotherapy.Frontiers in oncology · 2021Article
- Association between chronic kidney disease and mortality in stage IV cancer.International journal of clinical oncology · 2020Observational
- Defining Undertreatment and Overtreatment in Older Adults With Cancer: A Scoping Literature Review.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2020Article
- Perspectives from the Cancer and Aging Research Group: Caring for the vulnerable older patient with cancer and their caregivers during the COVID-19 crisis in the United States.Journal of geriatric oncology · 2020Article
- Inpatient palliative chemotherapy is associated with high mortality and aggressive end-of-life care in patients with advanced solid tumors and poor performance status.BMC palliative care · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeAlthough patients with incurable disease and Eastern Cooperative Oncology Group performance status (ECOG-PS ≥ 2) are underrepresented in clinical trials, they are frequently offered palliative chemotherapy (pCT) in daily clinical practice in order to improve symptoms and quality of life. In this case-control retrospective analysis, our goal was to identify factors associated with poorer survival and lack of benefit of pCT in this population. PATIENTS AND
methodsWe evaluated 2,514 patients who died between August 2011 and July 2012 in an academic cancer care institution and its hospice. A total of 301 patients with solid tumours and ECOG-PS ≥ 2 at prescription of pCT were selected for this case-control retrospective analysis. Cases were defined as patients who survived less than 90 days after the first cycle of first line pCT, and controls were those who had a longer survival.
results142 cases and 159 controls were included. Cases were more likely to experience grade ≥ 3 toxicity (43% versus 28%;
conclusionsThe independent predictors of short survival (less than 3 months) after initiation of pCT in this population were ECOG-PS > 2 and elevated sCr. Therefore, patient selection is crucial, as pCT may be deleterious in ECOG-PS ≥ 2 pts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.